Christopher Phillips, MD
Internal Medicine · Paducah, KYNPI 1912024563
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,420 of the $15,512 with a category attached, or 73.6%. 35 manufacturers reported payments, led by Pfizer at 28.1% of the total. Reporting peaked in 2021 at $5,405 and has fallen 66.1% since, to $1,834 in 2025. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 619 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- Amgen$3K
- UCB, Inc.$2K
- AbbVie$996
- Novartis$873
- Johnson & Johnson$402
- plus $3K from 29 others
Across 126 payments — averaging $2379.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$285K
- GSK$11K
- Ironwood Pharmaceuticals, Inc$3K
- Amgen$750
What the payments were for
- Consulting fees$4,07026%
- Food & beverage$11,42074%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $4,365 |
| Amgen(2 entities) | 204 | $3,482 |
| UCB, Inc. | 119 | $2,473 |
| AbbVie | 50 | $996 |
| Novartis | 51 | $873 |
| Johnson & Johnson(2 entities) | 23 | $402 |
| Lilly USA, LLC | 16 | $298 |
| GSK | 15 | $270 |
| Mallinckrodt Hospital Products Inc. | 11 | $243 |
| AstraZeneca(2 entities) | 13 | $242 |
| Organon | 13 | $204 |
| Genentech USA, Inc. | 12 | $201 |
| E.r. Squibb & Sons, L.L.C. | 13 | $199 |
| Sandoz | 9 | $184 |
| Boehringer Ingelheim | 5 | $171 |
| Sobi, Inc | 7 | $131 |
| Aurinia Pharma U.S., Inc. | 7 | $120 |
| Sanofi | 5 | $111 |
| Octapharma USA, Inc. | 4 | $103 |
| Merck | 6 | $101 |
| Radius Health, Inc. | 4 | $69 |
| Fresenius Kabi USA, LLC | 1 | $34 |
| Bristol Myers Squibb | 2 | $34 |
| Biogen | 1 | $24 |
| Boston Scientific | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Tonix Medicines, Inc. | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Avion Pharmaceuticals | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bimzelx$131
How this compares
$15,512 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 248 | $1,878,983 |
| Humira(Cf) PenAdalimumab | 191 | $1,627,293 |
| RinvoqUpadacitinib | 205 | $1,562,046 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $390,356 |
| OtezlaApremilast | 43 | $256,475 |
| Orencia ClickjectAbatacept | 45 | $254,495 |
| Xeljanz XrTofacitinib Citrate | 38 | $252,092 |
| HumiraAdalimumab | 20 | $224,053 |
| Cimzia (2 Pack)Certolizumab Pegol | 37 | $209,665 |
| TavneosAvacopan | 18 | $198,280 |
| KevzaraSarilumab | 42 | $181,933 |
| Humira(Cf)Adalimumab | 25 | $170,496 |
| TremfyaGuselkumab | 12 | $164,918 |
| EnbrelEtanercept | 22 | $164,290 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 17 | $146,954 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira, Humira(Cf), Savella | $996 | $1,966,588271 claims |
| AmgenOtezla, Tavneos, Enbrel | $3,482 | $619,04583 claims |
| Johnson & JohnsonTremfya, Simponi | $402 | $290,56525 claims |
| UCB, Inc.Cimzia (2 Pack) | $2,473 | $209,66537 claims |
| SanofiKevzara | $111 | $181,93342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Paducah
- Fares KhaterWhitesburg$412K
- Bernard BuchananOwensboro$185K
- David ManninoLexington$168K
- John PeppinCynthiana$108K
- Sanjay KaulBrownsville$69K
- John JonesHazard$63K
- Robert SasserLouisville$62K
- Justin LandeDanville$60K
- Sanjiv GuptaGrayson$49K
- Kelley McIntyreLouisville$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.